Phenglutarimide

DB13413

small molecule experimental

Deskripsi

Struktur Molekul 2D

Berat 288.391
Wujud -

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

552 Data
Aclidinium The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Aclidinium.
Mianserin Mianserin may increase the anticholinergic activities of Phenglutarimide.
Mirabegron The risk or severity of urinary retention can be increased when Phenglutarimide is combined with Mirabegron.
Potassium chloride The risk or severity of gastrointestinal ulceration can be increased when Phenglutarimide is combined with Potassium chloride.
Pramlintide The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Phenglutarimide.
Secretin porcine The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Phenglutarimide.
Tiotropium The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Tiotropium.
Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Phenglutarimide is combined with Topiramate.
Umeclidinium The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Umeclidinium.
Methylphenidate The risk or severity of adverse effects can be increased when Methylphenidate is combined with Phenglutarimide.
Dexmethylphenidate The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Phenglutarimide.
Metoclopramide The therapeutic efficacy of Phenglutarimide can be decreased when used in combination with Metoclopramide.
Glycopyrronium The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Glycopyrronium.
Botulinum toxin type A The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Botulinum toxin type A.
Glucagon Phenglutarimide may increase the gastrointestinal motility reducing activities of Glucagon.
Sulpiride Phenglutarimide may increase the anticholinergic activities of Sulpiride.
Botulinum toxin type B The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Botulinum toxin type B.
Eluxadoline The risk or severity of constipation can be increased when Phenglutarimide is combined with Eluxadoline.
Ramosetron The risk or severity of constipation can be increased when Phenglutarimide is combined with Ramosetron.
Naltrexone The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Naltrexone.
Bezitramide The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Bezitramide.
Tramadol The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Tramadol.
Morphine The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Morphine.
Codeine The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Codeine.
Hydromorphone The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Hydromorphone.
Methadone The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Methadone.
Meperidine The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Meperidine.
Oxycodone The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Oxycodone.
Butorphanol The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Butorphanol.
Dextropropoxyphene The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Dextropropoxyphene.
Pentazocine The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Pentazocine.
Sufentanil The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Sufentanil.
Alfentanil The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Alfentanil.
Fentanyl The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Fentanyl.
Nalbuphine The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Nalbuphine.
Levorphanol The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Levorphanol.
Remifentanil The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Remifentanil.
Buprenorphine The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Buprenorphine.
Hydrocodone The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Hydrocodone.
Diphenoxylate The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Diphenoxylate.
Oxymorphone The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Oxymorphone.
Dezocine The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Dezocine.
Levacetylmethadol The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Levacetylmethadol.
Methadyl acetate The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Methadyl acetate.
Dihydroetorphine The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Dihydroetorphine.
Diamorphine The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Diamorphine.
Ethylmorphine The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Ethylmorphine.
Etorphine The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Etorphine.
Dextromoramide The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Dextromoramide.
Desomorphine The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Desomorphine.
Carfentanil The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Carfentanil.
Dihydrocodeine The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Dihydrocodeine.
Alphacetylmethadol The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Alphacetylmethadol.
Dihydromorphine The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Dihydromorphine.
Tapentadol The risk or severity of urinary retention and constipation can be increased when Phenglutarimide is combined with Tapentadol.
Ketobemidone The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Ketobemidone.
DPDPE The risk or severity of adverse effects can be increased when Phenglutarimide is combined with DPDPE.
Lofentanil The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Lofentanil.
Opium The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Opium.
Normethadone The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Normethadone.
Piritramide The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Piritramide.
Alphaprodine The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Alphaprodine.
Nicomorphine The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Nicomorphine.
Meptazinol The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Meptazinol.
Phenoperidine The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Phenoperidine.
Phenazocine The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Phenazocine.
Tilidine The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Tilidine.
Carfentanil, C-11 The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Carfentanil, C-11.
Benzhydrocodone The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Benzhydrocodone.
Naloxegol The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Naloxegol.
Trospium The risk or severity of adverse effects can be increased when Trospium is combined with Phenglutarimide.
Oxyphenonium The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Phenglutarimide.
Benzatropine The risk or severity of adverse effects can be increased when Benzatropine is combined with Phenglutarimide.
Disopyramide The risk or severity of adverse effects can be increased when Disopyramide is combined with Phenglutarimide.
Metixene The risk or severity of adverse effects can be increased when Metixene is combined with Phenglutarimide.
Terfenadine The risk or severity of adverse effects can be increased when Terfenadine is combined with Phenglutarimide.
Buclizine The risk or severity of adverse effects can be increased when Buclizine is combined with Phenglutarimide.
Trihexyphenidyl The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Phenglutarimide.
Oxyphencyclimine The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Phenglutarimide.
Procyclidine The risk or severity of adverse effects can be increased when Procyclidine is combined with Phenglutarimide.
Hyoscyamine The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Phenglutarimide.
Methscopolamine bromide The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Phenglutarimide.
Darifenacin The risk or severity of adverse effects can be increased when Darifenacin is combined with Phenglutarimide.
Tridihexethyl The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Phenglutarimide.
Anisotropine methylbromide The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Phenglutarimide.
Atropine The risk or severity of adverse effects can be increased when Atropine is combined with Phenglutarimide.
Nicardipine The risk or severity of adverse effects can be increased when Nicardipine is combined with Phenglutarimide.
Mecamylamine The risk or severity of adverse effects can be increased when Mecamylamine is combined with Phenglutarimide.
Pirenzepine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Phenglutarimide.
Homatropine methylbromide The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Phenglutarimide.
Benzquinamide The risk or severity of adverse effects can be increased when Benzquinamide is combined with Phenglutarimide.
Propantheline The risk or severity of adverse effects can be increased when Propantheline is combined with Phenglutarimide.
Dicyclomine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Phenglutarimide.
Tropicamide The risk or severity of adverse effects can be increased when Tropicamide is combined with Phenglutarimide.
Cocaine The risk or severity of adverse effects can be increased when Cocaine is combined with Phenglutarimide.
Quinidine The risk or severity of adverse effects can be increased when Quinidine is combined with Phenglutarimide.
Amantadine The risk or severity of adverse effects can be increased when Amantadine is combined with Phenglutarimide.
Methantheline The risk or severity of adverse effects can be increased when Methantheline is combined with Phenglutarimide.
Cycrimine The risk or severity of adverse effects can be increased when Cycrimine is combined with Phenglutarimide.
Cyclopentolate The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Phenglutarimide.

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul